REG - Allergy Therapeutics - Block Listing Interim Review

Allergy TherapeuticsAnnouncement

02/08/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220802:nRSB6513Ua&default-theme=true

RNS Number : 6513U  Allergy Therapeutics PLC  02 August 2022

Allergy Therapeutics plc

Block Listing Interim Review

 

 

Date 2 August 2022

 

 Name of applicant:                                                                ALLERGY THERAPEUTICS PLC
 Name of scheme:                                                                   Allergy Therapeutics plc 2013 Long Term Incentive Plan
 Period of return:                        From:                                    1 February 2022             To:                         31 July 2022
 Number and class of share(s) (amount of stock / debt securities) originally       10,000,000 ordinary shares of 0.1p each in the Company admitted to trading on
 listed and the date of admission:                                                 24 November 2017
 Balance of unallotted securities under scheme(s) from previous return:            7,118,772
 Plus:  The amount by which the block scheme(s) has been increased since the       0
 date of the last return (if any increase has been applied for):
 Less:  Number of securities issued/allotted under scheme(s) during period:        0
 Equals:  Balance under scheme(s) not yet issued/allotted at end of period:        7,118,772

 

 Name of contact:              Sara Goldsbrough
 Telephone number of contact:  +44 (0) 7966 165719

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLREAFPAESKAEFA